ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings
ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 独立董事关于第五届董事会第五次会议相关事项的独立意见 | 2021-09-30 | Chinese | |
| 监事会关于2021年限制性股票激励计划激励对象名单（截至授予日）的核查意见 | 2021-09-30 | Chinese | |
| 上海荣正投资咨询股份有限公司关于睿智医药科技股份有限公司2021年限制性股票激励计划调整及授予相关事项之独立财务顾问报告 | 2021-09-30 | Chinese | |
| 关于独立董事取得独立董事资格证书的公告 | 2021-09-30 | Chinese | |
| 关于向激励对象授予限制性股票的公告 | 2021-09-30 | Chinese | |
| 第五届董事会第五次会议决议公告 | 2021-09-30 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2021
15 filings
| |||||
| 36036474 | 独立董事关于第五届董事会第五次会议相关事项的独立意见 | 2021-09-30 | Chinese | ||
| 36036465 | 监事会关于2021年限制性股票激励计划激励对象名单（截至授予日）的核查意见 | 2021-09-30 | Chinese | ||
| 36036455 | 上海荣正投资咨询股份有限公司关于睿智医药科技股份有限公司2021年限制性股票激励计划调整及授予相关事项之独立财务顾问报告 | 2021-09-30 | Chinese | ||
| 36036443 | 关于独立董事取得独立董事资格证书的公告 | 2021-09-30 | Chinese | ||
| 36036434 | 关于向激励对象授予限制性股票的公告 | 2021-09-30 | Chinese | ||
| 36036422 | 第五届董事会第五次会议决议公告 | 2021-09-30 | Chinese | ||
| 36036413 | 关于调整2021年限制性股票激励计划相关事项的公告 | 2021-09-30 | Chinese | ||
| 36036401 | 第五届监事会第四次会议决议公告 | 2021-09-30 | Chinese | ||
| 36036363 | 关于召开2021年第四次临时股东大会的法律意见书 | 2021-09-29 | Chinese | ||
| 36036348 | 2021年第四次临时股东大会决议公告 | 2021-09-29 | Chinese | ||
| 36036341 | 监事会关于公司2021年限制性股票激励计划激励对象之审核意见及公示情况说明 | 2021-09-24 | Chinese | ||
| 36036333 | 关于2021年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告 | 2021-09-24 | Chinese | ||
| 36036293 | 北京国枫律师事务所关于睿智医药科技股份有限公司2021年限制性股票激励计划的法律意见书 | 2021-09-13 | Chinese | ||
| 36036286 | 第五届监事会第三次会议决议公告 | 2021-09-13 | Chinese | ||
| 36036278 | 第五届董事会第四次会议决议公告 | 2021-09-13 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
ChemPartner PharmaTech Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55161/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55161 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55161 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55161 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55161}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ChemPartner PharmaTech Co., Ltd. (id: 55161)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.